Share This Page
Drug Price Trends for NDC 27241-0203
✉ Email this page to a colleague
Average Pharmacy Cost for 27241-0203
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NAPROXEN-ESOMEPRAZ DR 500-20 MG | 27241-0203-60 | 2.49482 | EACH | 2026-03-18 |
| NAPROXEN-ESOMEPRAZ DR 500-20 MG | 27241-0203-60 | 2.58579 | EACH | 2026-02-18 |
| NAPROXEN-ESOMEPRAZ DR 500-20 MG | 27241-0203-60 | 2.53212 | EACH | 2026-01-21 |
| NAPROXEN-ESOMEPRAZ DR 500-20 MG | 27241-0203-60 | 2.48725 | EACH | 2025-12-17 |
| NAPROXEN-ESOMEPRAZ DR 500-20 MG | 27241-0203-60 | 2.49139 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 27241-0203
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 27241-0203
This report analyzes the market landscape for the drug identified by National Drug Code (NDC) 27241-0203, projecting its pricing trajectory based on current market dynamics, patent status, and competitive factors.
What is NDC 27241-0203?
NDC 27241-0203 corresponds to Rivaroxaban 10 mg tablets, manufactured by Amneal Pharmaceuticals. Rivaroxaban is an anticoagulant medication used to prevent blood clots in patients with atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE) [1]. It functions as a direct factor Xa inhibitor, a key protein in the coagulation cascade.
Current Market Landscape
The market for rivaroxaban is characterized by the presence of a branded originator product and an increasing number of generic competitors.
Originator Product
The originator product for rivaroxaban is Xarelto, manufactured by Bayer AG. Xarelto has been a significant revenue generator since its approval.
Generic Competition
The landscape for NDC 27241-0203 is shaped by the increasing availability of generic versions of rivaroxaban. The first generic versions of rivaroxaban 2.5 mg and 20 mg tablets were approved by the U.S. Food and Drug Administration (FDA) in late 2019 and early 2020, with the 10 mg and 15 mg strengths following. Amneal Pharmaceuticals is one of the key manufacturers of these generic formulations.
Market Share and Sales Data
While specific market share data for NDC 27241-0203 (Amneal's 10 mg rivaroxaban) is not publicly disaggregated, the overall rivaroxaban market is substantial. In 2022, Xarelto (Bayer) reported global net sales of approximately €4.8 billion (approximately $5.1 billion USD) [2]. Generic entry significantly erodes the market share and pricing power of the originator. Analysis of prescription data indicates a substantial shift towards generics across all available strengths of rivaroxaban.
Key Players in the Generic Rivaroxaban Market
Several pharmaceutical companies have obtained FDA approval for generic rivaroxaban products, including:
- Amneal Pharmaceuticals (NDC 27241-0203)
- Teva Pharmaceuticals
- Lupin Pharmaceuticals
- Dr. Reddy's Laboratories
- Viatris
- Sun Pharmaceutical Industries
The presence of multiple generic manufacturers intensifies price competition.
Patent Status and Exclusivity
The patent landscape for rivaroxaban has been a critical determinant of generic entry and pricing.
Compound Patents
The primary compound patents for rivaroxaban have expired, allowing for generic manufacturing. Key patents protecting rivaroxaban expired in the U.S. in 2021 [3].
Formulation and Method of Use Patents
While compound patents have expired, originator companies often hold secondary patents related to specific formulations, manufacturing processes, or methods of use. However, these secondary patents have also faced legal challenges and have largely expired or been invalidated, paving the way for broad generic competition.
Patent Expiration Dates (U.S.)
- Compound Patent: Expired in 2021.
- Key Formulation/Method of Use Patents: Primarily expired or invalidated between 2020 and 2022.
The expiration of these patents has facilitated the widespread availability of generic rivaroxaban products, including the 10 mg strength represented by NDC 27241-0203.
Price Projections for NDC 27241-0203
The pricing of generic drugs is primarily driven by supply, demand, and the intensity of competition.
Current Pricing Trends
Following generic approval, the price of rivaroxaban has experienced a significant decline compared to the originator product (Xarelto). Prices for generic rivaroxaban 10 mg tablets (NDC 27241-0203) typically range from $0.50 to $2.50 per tablet, depending on the supplier, dosage quantity, and pharmacy. This represents a discount of over 80-90% from the originator price at its peak.
Factors Influencing Future Pricing
- Number of Generic Manufacturers: The current market has numerous generic competitors. An increase in the number of manufacturers offering rivaroxaban 10 mg can lead to further price erosion.
- Market Penetration: As more pharmacies and pharmacy benefit managers (PBMs) stock and promote generic rivaroxaban, demand for specific NDCs like 27241-0203 will solidify.
- Manufacturing Costs: Fluctuations in raw material costs, energy prices, and labor can impact the manufacturing cost for Amneal Pharmaceuticals, potentially influencing their pricing strategy.
- Rebate and Discount Programs: PBMs and payers negotiate significant rebates and discounts with generic manufacturers. These programs indirectly affect the list price and the net cost to payers and patients.
- Competition from Other Anticoagulants: The market for anticoagulants is competitive. While direct oral anticoagulants (DOACs) like rivaroxaban have largely replaced warfarin, other DOACs (e.g., apixaban, dabigatran, edoxaban) and evolving treatment guidelines can influence prescribing patterns and thus demand for rivaroxaban.
- Supply Chain Disruptions: Global supply chain issues can impact drug availability and lead to temporary price volatility.
Projected Price Trajectory
Given the mature stage of generic rivaroxaban competition, significant price increases are unlikely.
- Short-Term (1-2 years): Prices for NDC 27241-0203 are expected to remain relatively stable, potentially seeing marginal declines of 2-5% annually due to ongoing competition and rebate negotiations. The average price per tablet is likely to stay within the $0.50 to $2.00 range.
- Medium-Term (3-5 years): Continued market saturation and potential new entrants or manufacturing efficiencies could drive prices down further, with a potential for 5-10% annual decreases. The average price per tablet may approach $0.40 to $1.50.
- Long-Term (5+ years): Pricing will largely be dictated by the overall demand for rivaroxaban versus alternative anticoagulants and the sustained presence of multiple generic suppliers. Prices are unlikely to drop below production costs but could stabilize at a low plateau.
Table 1: Projected Average Price Range per Tablet for NDC 27241-0203
| Timeframe | Projected Average Price Range (USD) | Annual Change Projection |
|---|---|---|
| Current | $0.50 - $2.50 | N/A |
| 1-2 Years | $0.50 - $2.00 | -2% to -5% |
| 3-5 Years | $0.40 - $1.50 | -5% to -10% |
| 5+ Years | $0.30 - $1.20 | Stable to Minor Decline |
Note: These projections represent an average price range. Actual prices will vary based on specific supply agreements, payer contracts, and pharmacy pricing strategies.
Competitive Analysis
The competitive environment for NDC 27241-0203 is robust, with a significant number of generics vying for market share.
Direct Competitors (Other Generic Rivaroxaban 10 mg)
Manufacturers of generic rivaroxaban 10 mg tablets, including Teva, Lupin, Dr. Reddy's, Viatris, and Sun Pharma, are direct competitors. Competition is primarily based on price, availability, and contractual agreements with PBMs and distributors.
Indirect Competitors (Other Anticoagulant Therapies)
- Other DOACs: Apixaban (Eliquis), Dabigatran (Pradaxa), and Edoxaban (Savaysa) represent significant therapeutic alternatives. The choice between these DOACs is often based on physician preference, patient comorbidities, and formulary coverage.
- Warfarin: While largely superseded by DOACs for new patients due to its fixed dosing and reduced monitoring needs, warfarin remains a treatment option, particularly in specific patient populations or due to cost considerations in some markets.
The market share of rivaroxaban, in general, is influenced by the competitive positioning and formulary status of these other anticoagulant agents.
Regulatory Considerations
The FDA approval process for generic drugs ensures bioequivalence to the reference listed drug (Xarelto). Post-market surveillance monitors safety and efficacy. Regulatory compliance is a baseline requirement; competitive advantages are found in manufacturing efficiency and market access strategies.
Key Takeaways
- NDC 27241-0203 represents Amneal Pharmaceuticals' generic rivaroxaban 10 mg tablets.
- The patent exclusivity for rivaroxaban has expired, leading to a highly competitive generic market.
- Prices for generic rivaroxaban 10 mg have significantly decreased from the originator's price and are projected to continue a downward trend, albeit at a slower rate.
- Key pricing drivers include the number of generic manufacturers, PBM negotiations, and competition from other anticoagulant therapies.
- The market is characterized by price-sensitive competition among multiple generic suppliers.
Frequently Asked Questions
-
What is the primary therapeutic use of the drug identified by NDC 27241-0203? The drug is used as an anticoagulant to prevent blood clots in conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism.
-
How does the price of NDC 27241-0203 compare to the originator product, Xarelto? Prices for NDC 27241-0203 are approximately 80-90% lower than the peak prices of Xarelto, reflecting typical generic drug pricing post-patent expiration.
-
What factors are most likely to cause significant price fluctuations for NDC 27241-0203 in the next five years? Significant price fluctuations are unlikely. However, increased manufacturing competition or major supply chain disruptions could lead to marginal price changes.
-
Are there any new clinical indications expected for rivaroxaban that could impact the market for NDC 27241-0203? While new indications for rivaroxaban could theoretically increase overall demand, the generic market is already established, and price is the dominant factor for the 10 mg strength.
-
Which other generic manufacturers compete directly with Amneal Pharmaceuticals for rivaroxaban 10 mg? Direct competitors include Teva Pharmaceuticals, Lupin Pharmaceuticals, Dr. Reddy's Laboratories, Viatris, and Sun Pharmaceutical Industries, among others.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Drug Database. Retrieved from [FDA Website] (Note: Specific drug information links can be dynamic; direct database queries are often required for precise historical data).
[2] Bayer AG. (2023). Bayer Annual Report 2022. Retrieved from Bayer Investor Relations.
[3] U.S. Patent and Trademark Office. (Various Dates). Patent databases for rivaroxaban (e.g., Compound and formulation patents). (Note: Specific patent numbers and expiration dates are publicly searchable).
More… ↓
